Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Quanterix Corp(QTRX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for QTRX
10/02/2026: QTRX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Quanterix Corp is a life sciences tools company that specializes in ultra-sensitive protein detection platforms used primarily for neurodegenerative disease research and drug development. Its primary strength lies in its proprietary Simoa technology, which provides a high-value, niche position in the market by identifying biomarkers that are otherwise undetectable. The investment story centers on the company's ability to transition from research-focused instrumentation to more lucrative clinical diagnostic applications. Key risks include intense competition from well-capitalized industry giants and the execution challenges of moving into the clinical space. The stock may best suit growth-oriented investors who can monitor progress in product adoption and potential clinical commercialization milestones.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company operates in a high-growth proteomics niche with significant long-term potential in clinical diagnostics. |
| Momentum investor | Mixed fit | Momentum is highly conditional on product adoption cycles and the successful translation of research tools into clinical revenue. |
| Value investor | Weak fit | As a growth-stage company that is not yet consistently profitable, it does not fit traditional value metrics. |
| Dividend investor | Weak fit | The company reinvests all capital into growth and does not pay a dividend. |
| Low-risk investor | Weak fit | High inherent volatility and the speculative nature of biotech tools make this unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is susceptible to fluctuations based on clinical trial news and technology adoption milestones. |
| Valuation risk | Medium / high | Valuation is sensitive to long-term growth expectations rather than current earnings multiples. |
| Competition risk (Consolidation/Life Science Giants) | High | Larger companies with more resources could potentially erode the competitive edge of Quanterix's niche offerings. |
| Business quality | Medium | While the technology is innovative, the business model relies heavily on building a recurring revenue base from consumables. |
| Dividend income | Low / none | There is no current or planned dividend payout to provide yield-based support. |
| Execution risk | Medium / high | Translating research-grade technology into standardized clinical diagnostic use remains a significant operational challenge. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -70.05% | Avg. Invested days 14 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/02/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 172.15M USD | Price to earnings Ratio - | 1Y Target Price 3 |
Price to earnings Ratio - | 1Y Target Price 3 | ||
Volume (30-day avg) 783.6K shares | Beta 1.04 | 52 Weeks Range 2.15 - 8.77 | Updated Date 10/02/2026 |
52 Weeks Range 2.15 - 8.77 | Updated Date 10/02/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.62 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Instruments | Revenue from the sale of HD-X and SR-X automated platforms. | Selling the core hardware allows the company to lock in customers for the long term. |
| Consumables | Revenue from proprietary kits and reagents used on the instruments. | This is a recurring revenue stream that grows as more instruments are installed in labs. |
| Services | Testing services and clinical trial support provided by Quanterix. | This provides additional revenue and helps validate the utility of their platforms for clinical use. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 89.30M | Price to Sales(TTM) 1.12 |
Enterprise Value 89.30M | Price to Sales(TTM) 1.12 | ||
Enterprise Value to Revenue 0.58 | Enterprise Value to EBITDA -1.49 | Shares Outstanding 47.29M | Shares Floating 38.01M |
Shares Outstanding 47.29M | Shares Floating 38.01M | ||
Percent Insiders 6.33 | Percent Institutions 71.22 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Quanterix Corp
Exchange NASDAQ | Headquarters Billerica, MA, United States | ||
IPO Launch date 2017-12-07 | President, CEO & Director Mr. Everett V. Cunningham | ||
Sector Healthcare | Industry Medical Devices | Full time employees 450 | Website https://www.quanterix.com |
Full time employees 450 | Website https://www.quanterix.com | ||
Quanterix Corporation, a life sciences company in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, the company offers contract research and clinical laboratory testing services, including research and clinical trial testing, and lucent diagnostic services. The company primarily operates in the areas of neurology, oncology and immunology, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and sales force and distributors. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.